Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Dividend

Remus Pharmaceuticals Limited has fixed September 22, 2026, as the record date for determining shareholder entitlement to a final dividend of Rs. 0.50 per share.

Remus Pharmaceuticals Annual General Meeting

Remus Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the migration of its equity shares from the NSE Emerge platform to Main Board.

Remus Pharmaceuticals Merger & Restructuring

Remus Pharmaceuticals will incorporate a new subsidiary in the Dominican Republic for pharmaceutical distribution. The company will hold at least 51% of its share capital.

Remus Pharmaceuticals Management Change

Remus Pharmaceuticals Limited has appointed Mr. Ashutosh Naginbhai Valani as a Non-Executive Independent Director, effective September 2, 2026.

Remus Pharmaceuticals SME to Main Board Migration

Remus Pharmaceuticals' board approved the company's migration from the NSE SME Emerge platform to the Main Board. It also announced a new subsidiary in the Dominican Republic.

Remus Pharmaceuticals Earnings Call: Key Takeaways

Remus Pharmaceuticals delivered 38% YoY consolidated revenue growth for FY26. Management is shifting focus toward higher-margin B2C segments and niche formulations in Latin America and Southeast Asia.

Remus Pharmaceuticals Earnings Call: Key Takeaways

Remus Pharmaceuticals delivered high double-digit revenue growth in H2FY26, driven by aggressive international B2C expansion in Latin America and new specialized therapy launches.

Remus Pharmaceuticals Earnings Call: Key Takeaways

Remus Pharmaceuticals reported FY26 consolidated revenue of ₹8,536 Mn, representing 37.6% growth. The company maintains an asset-light model focusing on complex specialty formulations in semi-regulated markets.

Remus Pharmaceuticals H2 FY26 Results: Net Profit ₹24.6 Cr, Up 19.4% YoY

Remus Pharmaceuticals Ltd reported revenue from operations of ₹453.4 Cr (+30.4% YoY) and net profit of ₹24.6 Cr (+19.4% YoY) for H2 FY26.

Key figure

Net profit ₹24.6 Cr · +19.4% YoY